The Metastatic Lung Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Lung Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Lung Cancer and features dormant and discontinued products.

GlobalData tracks 55 drugs in development for Metastatic Lung Cancer by 50 companies/universities/institutes. The top development phase for Metastatic Lung Cancer is preclinical with 38 drugs in that stage. The Metastatic Lung Cancer pipeline has 47 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Metastatic Lung Cancer pipeline products market are: Portage Biotech, Bristol-Myers Squibb and Polyplus-Transfection.

The key targets in the Metastatic Lung Cancer pipeline products market include Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4), Adenosine Receptor A2b (ADORA2B), and 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5).

The key mechanisms of action in the Metastatic Lung Cancer pipeline product include DNA Topoisomerase II (EC 5.99.1.3) Inhibitor with two drugs in IND/CTA Filed. The Metastatic Lung Cancer pipeline products include nine routes of administration with the top ROA being Intravenous and 15 key molecule types in the Metastatic Lung Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Metastatic Lung Cancer overview

Metastatic lung cancer, also known as stage IV lung cancer, is an advanced form of lung cancer characterized by the spread of cancerous cells from the lungs to distant parts of the body. It typically occurs when cancer cells break away from the primary tumor in the lungs and travel through the bloodstream or lymphatic system to other organs or tissues, forming secondary tumors. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both types can metastasize, but the most common type that spreads beyond the lungs is NSCLC.

For a complete picture of Metastatic Lung Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.